Our Pipeline

WE DISCOVERED, ARE DEVELOPING AND CONTROL WORLDWIDE RIGHTS TO OUR UROGUANYLIN  BASED GI PLATFORM

Our proprietary GI platform is based on uroguanylin, a naturally occurring human GI peptide, and includes TRULANCE and dolcanatide.

Uroguanylin Analog
Discovery Phase 1 Phase 2 Phase 3 NDA Filings Market
TRULANCE™ (plecanatide)
CIC Discovery Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
NDA Filings Phase in progress
Trulance (plecanatide)
Market Phase not started
IBS-C Discovery Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase complete
NDA Filings Phase in progress
Market Phase not started

Learn More

Dolcanatide (SP-333)
OIC Phase 2 Phase completed for OIC
Phase 2 Phase completed for OIC
Phase 2 Phase completed for OIC
Phase 2 Phase completed for OIC
Phase 2 Phase completed for OIC
Phase 2 Phase completed for OIC
UC Phase 1b Phase completed for UC
Phase 1b Phase completed for UC
Phase 1b Phase completed for UC
Phase 1b Phase completed for UC
Phase 1b Phase completed for UC
Phase 1b Phase completed for UC

Status of Dolcanatide Clinical Programs

  • Positive proof-of-concept study in patients with opioid-induced constipation (OIC) completed in November 2014
  • Positive proof-of-concept study in patients with ulcerative colitis (UC) completed in January 2016

Learn More

View clincal trials buttonView Clinical Trials